hotspot -WSS

hotspot

author：leisure time 2025-09-27 15:59:27 - browse：588

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Brain 'hot spot' may explain why African Americans feel greater pain

hotspot

WSS

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

The best solution to the drug shortages problem

Connecting traumatic brain injury and domestic violence

RaDonda Vaught case: a double standard for nurses, physicians

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

A new study asks: Are we harming blood donors by taking blood?

explore

hotspot

explore

Novavax promises a turnaround & Lilly roils the obesity market

Did the public have the right to know Arthur Ashe had AIDS?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Anavex keeps shifting the goalposts in its clinical trials

Medicare proposal to cover medical devices draws a mixed reaction

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

After affirmative action ruling, medical educators look to 'holistic review'

Did the public have the right to know Arthur Ashe had AIDS?

As demand for Covid shots wanes, Moderna seeks its next success

Listen: PBM conflicts, RSV vaccines, & the future of flu season

leisure time

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Community addresses injustice for Long Island mothers

Meta looks to target Twitter with a rival app called Threads

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Emergent cuts jobs, executive role in business shake

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

hotspot

hotspot

hotspot

hotspot